The Systemic Mastocytosis drugs in development market research report provides comprehensive information on the therapeutics under development for Systemic Mastocytosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Systemic Mastocytosis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Systemic Mastocytosis and features dormant and discontinued products.

GlobalData tracks 11 drugs in development for Systemic Mastocytosis by 11 companies/universities/institutes. The top development phase for Systemic Mastocytosis is phase ii with four drugs in that stage. The Systemic Mastocytosis pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Systemic Mastocytosis pipeline products market are: Blueprint Medicines, MacroGenics and Allakos.

The key targets in the Systemic Mastocytosis pipeline products market include Mast/Stem Cell Growth Factor Receptor Kit (Proto Oncogene c Kit or Tyrosine Protein Kinase Kit or v Kit Hardy Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog or Piebald Trait Protein or CD117 or KIT or EC 2.7.10.1), Platelet Derived Growth Factor Receptor Alpha (Alpha Type Platelet Derived Growth Factor Receptor or CD140 Antigen Like Family Member A or Platelet Derived Growth Factor Receptor 2 or CD140a or PDGFRA or EC 2.7.10.1), and Platelet Derived Growth Factor Receptor Beta (Beta Type Platelet Derived Growth Factor Receptor or CD140 Antigen Like Family Member B or Platelet Derived Growth Factor Receptor 1 or CD140b or PDGFRB or EC 2.7.10.1).

The key mechanisms of action in the Systemic Mastocytosis pipeline product include Mast/Stem Cell Growth Factor Receptor Kit (Proto Oncogene c Kit or Tyrosine Protein Kinase Kit or v Kit Hardy Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog or Piebald Trait Protein or p145 c Kit or CD117 or KIT or EC 2.7.10.1) Inhibitor with four drugs in Pre-Registration. The Systemic Mastocytosis pipeline products include four routes of administration with the top ROA being Oral and five key molecule types in the Systemic Mastocytosis pipeline products market including Small Molecule, and Monoclonal Antibody.

Systemic Mastocytosis overview

Systemic mastocytosis is a disorder where mast cells are abnormally increased in multiple organs including the bone marrow. Symptoms include shortness of breath, low blood pressure, hives and swelling, itching, diarrhea, headache, flushing, and musculoskeletal pain. Treatment includes antihistamines and more aggressive forms of medication, including interferon or chemotherapeutic agents.

For a complete picture of Systemic Mastocytosis’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.